Investor Presentation H1 2023
60
Investor presentation
First six months of 2023
Patient-centric strategy designed to activate more people with
obesity, drive HCP engagement, and improve market access
Million
people >764 million people
800
live with obesity
764
50
0
~10% seek help
~2% are treated
with an AOM
~2.5 million seen by
obesity experts
76
Treated ~1 million
with SaxendaⓇ in
2021
Only 25% on treatment
for more than 1 year
15
-2.5
[1]
0.25
Ensure obesity is a healthcare priority
needing medical management
People with obesity
activation
Truth
About
Weight™
HCP engagement
Rethink
ObesityⓇ
direct
care
obesity
Value proposition
to payers
SELECT
semaglutide effects on cardiovascular
outcomes in people with overweight or obesity
HCP: Healthcare providers; AOM: Anti-obesity medication; CagriSema: Cagrilintide in combination with semaglutide
Source: World Obesity Atlas 2022; IQVIA AOM TRX 12m PWO (People with Obesity); Market Research
Maximize the value of Novo Nordisk's
superior treatment solutions
Marketed product portfolio and pipeline closing the treatment gaps
Approved products
Saxenda®
Late-stage pipeline products
Oral semaglutide 50 mg
ONCE-WEEKLY
wegovyⓇ
liraglutide injection
semaglutide injection 2.4 mg
CagriSema
Novo NordiskⓇView entire presentation